Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company
The Healing Company Inc. (OTC: HLCO), a publicly traded company backed by Dr.
Psyched: VC Fund Invests $50M In Psychedelics, Musk’s ‘Exploratory Journeys’, Native American Use Of Peyote And More
Palo Santo Closes $50M Investment Fund
Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund.
Proprietary Psychedelic Readies For Trials Targeting Neurologic And Brain Disease
Canadian biotech company Lobe Sciences Ltd.
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
(Part four of a four-part series - Read part three)
Novel Psychedelic Compound Show Positive Results For Opioid Use Disorder Treatment
Kratom grows in several Asian countries and has been traditionally used by local communities as a natural home remedy for pain, depression and addiction.
Optimi Closes Non-Brokered Private Placement, Here Are The Details
Canadian licensed producer of GMP-grade psilocybin Optimi Health Corp.
Psyched: CA’s Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy
Canadian ‘Shrooms Kit Company Acquires Established Dutch Farm To Expand Production
Ontario-based producer of functional mushroom home grow kits and premium magic truffles Red Light Holland Corp. (OTC Pink: TRUFF) has acquired MiniChamp B.V., a dutch home grow mushroom farm, through its wholly-owned subsidiary RLH Netherlands B.V.
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Being the sole psychedelic legally available as medicine, ketamine-assisted therapy services are expanding at a rapid pace across the U.S.
EXCLUSIVE: atai’s Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).